Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The serrated polyp pathway to colorectal carcinoma. Mini-symposium: pathology of the large bowel.Diagn Histopathol. 2008; 14
- Genetic alterations during colorectal tumor development.N Engl J Med. 1988; 319: 525-532
- Molecular classification and correlates in colorectal cancer.J Mol Diagn. 2008; 10: 13-27
- Epithelial neoplasms of the large intestine.in: Odze R.D. Goldblum J.R. Surgical pathology of the GI tract, liver, biliary tract and pancreas. 2nd edition. ExpertConsult, Saunders Elsevier, Pennsylvania, Philadelphia2004
- The other colonic polyposis syndromes.ANZ J Surg. 2012; 82: 675-681
- What the physician needs to know about Lynch syndrome: an update.Oncology. 2005; 19: 455-463
- The genetics of HNPCC: application to diagnosis and screening.Crit Rev Oncol Hematol. 2006; 58: 208-220
- New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing.Gastroenterology. 2006; 130: 577-587
- A new variant database for mismatch repair genes associated with Lynch syndrome.Hum Mutat. 2007; 28: 669-673
- APC mutations in sporadic colorectal tumors: a mutational ‘‘hotspot’’ and interdependence of the ‘‘two hits’’.Proc Natl Acad Sci USA. 2000; 97: 3352-3357
- The gastrointestinal tract.in: Kumar V. Abbas A.K. Fausto N. Robbins and Cotran pathologic basis of disease. 8th edition. Studentconsult, Suanders Elsevier, Philadelphia, Pennsylvania2010: 763-832
- Carcinogenesis in the GI tract: from morphology to genetics and back again.Mod Pathol. 2001; 14: 236-245
- Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5’ part of MSH2.Cancer Prev Res (Phila). 2011; 4: 1556-1562
- Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.Histopathology. 2007; 50: 113-130
- Microsatellite instability in cancer of the proximal colon.Science. 1993; 260: 816-819
- Multistep progression of colorectal cancer in the setting of microsatellite instability: new details and novel insights.Gastroenterology. 2001; 121: 1497-1502
- Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.Science. 1995; 268: 1336-1338
- Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.J Natl Cancer Inst. 2004; 96: 261-268
NCCN clinical practice guidelines in oncology (NCCN guidelines). Colon cancer. Version 3. 2013. Available at: nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed May 2, 2013.
- Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.Lancet. 2007; 370: 2020-2029
- Molecular diagnostics of colorectal cancer.Arch Pathol Lab Med. 2011; 135: 578-587
- A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.Cancer Res. 1998; 58: 5248-5257
- Hyperplastic and serrated polyps of the colorectum.Gastroenterol Clin North Am. 2007; 36: 947-968
- The serrated pathway to colorectal carcinoma: current concepts and challenges.Histopathology. 2013; 62: 367-386
- Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.Nature. 2002; 418: 934
- APC germline mutations in individuals being evaluated for familial adenomatous polyposis. A review of the Mayo Clinic experience with 1591 consecutive tests.J Mol Diagn. 2013; 15: 31-43
- Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma.Cancer. 2001; 91: 2417-2422
- Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA).Cancer. 2012; 118: 6039-6045
- Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.J Clin Oncol. 2007; 25: 2198-2204
- Mutations of the BRAF gene in human cancer.Nature. 2002; 417: 949-954
- CpG island methylator phenotype in colorectal cancer.Proc Natl Acad Sci U S A. 1999; 96: 8681-8686
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.Nat Genet. 2006; 38: 787-793
- Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas. A report of the Association for Molecular Pathology.J Mol Diagn. 2012; 14: 91-103
- Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.Am J Surg Pathol. 1999; 23: 1248-1255
- Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.N Engl J Med. 2003; 249: 247-257
- Identification of a poor-prognosis BRAF-mutant–like population of patients with colon cancer.J Clin Oncol. 2012; 20: 1288-1295
- QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients.Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22: 3501
- Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.J Clin Oncol. 2010; 28: 3219-3226
- Role of cyclooxygenase inhibitors for the prevention of colorectal cancer.Gastroenterol Clin North Am. 2001; 30: 1001-1010
- Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes.Cancer Res. 1996; 56: 4836-4840
- Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.Proc Natl Acad Sci U S A. 2007; 104: 18654-18659
- Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma.Histopathology. 2011; 58: 679-692
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in kras codon 12 and 13 wild-type metastatic colon cancer.Br J Cancer. 2009; 101: 715-721
- High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.Gastroenterology. 2006; 131: 1400-1407
- Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J Clin Oncol. 2008; 26: 1626-1634
- KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.J Clin Oncol. 2008; 26: 374-379
- Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly.Surg Today. 2005; 35: 442-445
- Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.J Clin Oncol. 2002; 20: 1043-1048
- Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.J Natl Cancer Inst. 2007; 99: 291-299
- Molecular staging individualizing cancer management.J Surg Oncol. 2012; 105: 468-474
- Novel molecular screening approaches in colorectal cancer.J Surg Oncol. 2012; 105: 459-467
- Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high risk colon cancer.J Clin Oncol. 1998; 16: 295-300
- KRAS mutations are associated with specific morphologic features in colon cancer.J Clin Gastroenterol. 2013; 47: 509-514
- Updates in gastrointestinal oncology–insights from the 2008 44th annual meeting of the American Society of Clinical Oncology.J Hematol Oncol. 2009; 2: 9
- Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?.Cancer Treat Rev. 2010; 36: S56-S61https://doi.org/10.1016/S0305-7372(10)70021-9
- Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study.Br J Cancer. 2001; 85: 692-696
- Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium.J Cell Physiol. 2007; 210: 740-749
- Cancer facts & figures 2013.American Cancer Society, Atlanta (GA)2013 (Available at:)
- Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol. 2008; 26: 5705-5712
- Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention.Lancet Oncol. 2002; 3: 166-174
- Chemoprevention of colorectal cancer.Am J Gastroenterol. 2002; 97: 13-21
- Systemic treatment of colorectal cancer.Eur J Cancer. 2002; 38: 1000-1015
- Adjuvant treatment of colorectal cancer.CA Cancer J Clin. 2007; 57: 168-185
- Diagnostic and prognostic significance of serum MicroRNAs in colorectal cancer.J Surg Oncol. 2013; 107: 217-220
- Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.Int J Cancer. 2012; 132: 1004-1012
Article info
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
